Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81%
Regeneron’s monoclonal antibody cocktail for Covid-19 continues to impress, this time in a joint trial with NIH that found the normally infused treatment works as a preventive subcutaneous injection.
The trial showed that REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic infections by 81% in those who did not have Covid before the trial within 29 days. There were 11 cases in the 753-person mAb arm, versus 59 cases in the 752-person placebo arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
